Brainfarma Indústria Química e Farmacêutica S/A
Clinical trials sponsored by Brainfarma Indústria Química e Farmacêutica S/A, explained in plain language.
Brazilian pharmaceutical company producing generic and branded medicines.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a new cosmetic pass the sensitive skin test? Results expected Sep 2026 (estimated)
- Can a daily cosmetic keep pores clear without irritation? Results expected Sep 2026 (estimated)
- Can a daily cream rebuild the Skin's barrier? trial puts moisturizer to the test Results expected Nov 2026 (estimated)
- A new gel aims to fade dark Spots—Will it deliver a brighter complexion? Results expected Jan 2027 (estimated)
- Could a Once-Daily pill ease nerve pain just as well as the standard Twice-Daily dose? Results expected Jun 2027 (estimated)
-
Can a daily cosmetic keep pores clear without irritation?
Symptom relief Recruiting nowThis trial evaluates whether a cosmetic product called Blancy Pro is safe and gentle for daily use on oily, acne-prone skin. About 33 women aged 18 to 45 will apply the product for 28 days under normal conditions. Researchers will check for skin irritation, discomfort, and whethe…
Sponsor: Brainfarma Industria Química e Farmacêutica S/A • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
A new gel aims to fade dark Spots—Will it deliver a brighter complexion?
Symptom relief Recruiting nowThis trial tests whether a depigmenting gel cream called Blancy Pro can reduce facial hyperpigmentation, including dark spots and melasma. Forty women aged 30 to 60 will apply the product daily for 90 days. Researchers will measure skin lightening using a colorimeter and clinical…
Sponsor: Brainfarma Industria Química e Farmacêutica S/A • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Can a daily cream rebuild the Skin's barrier? trial puts moisturizer to the test
Symptom relief Recruiting nowResearchers are testing a moisturizing cream in 22 adults aged 36 to 65 with moderate to severe dry skin on their lower legs. Participants apply the cream twice daily for 28 days. Dermatologists check for irritation, and instruments measure skin hydration and how well the skin ba…
Sponsor: Brainfarma Industria Química e Farmacêutica S/A • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Can a new cosmetic pass the sensitive skin test?
Symptom relief Recruiting nowThis trial evaluates whether Blancy Pro, a cosmetic product, is safe and gentle enough for people with sensitive skin. About 33 women aged 18 to 60 with clinically confirmed sensitive skin will use the product, and researchers will check for any skin or eye irritation. The goal i…
Sponsor: Brainfarma Industria Química e Farmacêutica S/A • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Could a Once-Daily pill ease nerve pain just as well as the standard Twice-Daily dose?
Symptom relief Recruiting nowThis phase 3 trial tests whether an extended-release (once-daily) form of pregabalin works as well as the standard immediate-release (twice-daily) form for relieving nerve pain caused by diabetic peripheral neuropathy or postherpetic neuralgia. About 348 adults aged 18 to 75 with…
Phase 3 • Sponsor: Brainfarma Industria Química e Farmacêutica S/A • Aim: Symptom relief
Last updated Jul 22, 2026 00:00 UTC
-
New Triple-Action pill takes on cold and flu symptoms
Symptom relief Recruiting nowThis study tests a new pill containing three ingredients (dipyrone, caffeine, and chlorpheniramine) to see if it works as well as a standard cold medicine for relieving stuffy nose and other cold and flu symptoms. About 620 adults with early cold or flu symptoms will take either …
Phase 3 • Sponsor: Brainfarma Industria Química e Farmacêutica S/A • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC